Soleno Therapeutics, Inc. (SLNO)
52.57
0.00 (0.00%)
USD |
NASDAQ |
Apr 16, 16:00
52.58
+0.01
(+0.02%)
After-Hours: 20:00
Soleno Therapeutics Research and Development Expense (Quarterly) : 9.558M for Dec. 31, 2025
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Neurocrine Biosciences, Inc. | 258.20M |
| Nektar Therapeutics | 29.68M |
| Boston Scientific Corp. | 569.00M |
| Integer Holdings Corp. | 10.11M |
| Molina Healthcare, Inc. | -- |